Several PLA2 inhibitors, including sPLA2 blockers, have been evaluated in clinical trials for the treatment of osteoarthritis, rheumatoid arthritis, atherosclerosis, sepsis and atopic dermatitis, among others, but none has reached the market (Nikolaou et al., 2019). This evidence concerns the gene PLA2G6 and Sepsis.